One of America's biggest companies is imploding
The crisis engulfing UnitedHealth hit a crescendo this week when CEO Andrew Witty stepped down abruptly for 'personal reasons.'
UnitedHealth also swiftly abandoned its financial guidance, blaming skyrocketing medical costs.
And then The Wall Street Journal dropped the hammer, revealing that UnitedHealth is under federal criminal investigation for possible Medicare fraud.
The developments have stunned investors, triggering a dramatic loss of confidence. UnitedHealth's (UNH) stock has lost half its value – a staggering $288 billion – in the span of a month. Its share price plunged on Thursday to its lowest level since April 2020, during the height of the pandemic.
It's a spectacular reversal of fortunes for one of America's most powerful companies and the nation's largest health insurer.
The trouble at UnitedHealth comes almost exactly six months after the murder of Brian Thompson, one of its top executives. The brazen shooting of Thompson, in Midtown Manhattan, captured international attention and surfaced deep public resentment toward the healthcare industry.
The UnitedHealth selloff gathered steam on Thursday, with the Journal report of a federal criminal investigation driving UnitedHealth shares down another 13%, leaving them on track for their worst week since 1998, according to FactSet data.
The DOJ's healthcare-fraud unit is overseeing an investigation into possible Medicare fraud at UnitedHealth, the Journal reported.
UnitedHealth responded to the report by posting a statement online that described the Journal's reporting as 'deeply irresponsible' because the paper acknowledged the precise nature of the potential criminal allegations is unclear.
'We have not been notified by the Department of Justice of the supposed criminal investigation reported, without official attribution, in the Wall Street Journal today,' UnitedHealth said in the statement. 'We stand by the integrity of our Medicare Advantage program.'
The DOJ declined to comment.
Jeffrey Sonnenfeld, founder of the Yale Chief Executive Leadership Institute, said the abrupt nature of the CEO transition at UnitedHealth is quite telling.
'The fact the board moved with this much speed means they obviously lost confidence in the CEO. It's got to be pretty bad if they moved this fast,' Sonnenfeld said. 'It's astounding.'
UnitedHealth described the CEO switch as a decision Witty made 'for personal reasons' and the company said he has agreed to serve as a senior adviser. But Sonnenfeld suspects Witty was forced out.
''Personal reasons' is the humiliation of this implosion,' he said.
UnitedHealth is turning to a familiar face to clean up the mess: Stephen Hemsley, its former longtime CEO and current chairman.
Hemsley praised Witty for displaying 'real integrity and compassion during one of the most difficult periods any company could endure.'
The new CEO also, however, made clear his displeasure with UnitedHealth's stumbles.
'To all stakeholders, including employees and shareholders, I am deeply disappointed in and apologize for the performance setbacks we have encountered from both external and internal challenges,' Hemsley said during a conference call on Tuesday.
Sonnenfeld hailed the decision by UnitedHealth's board to bring back Hemsley, who led the company to success between 2006 and 2017.
'He does know where the bodies are buried, and he's the perfect guy to go to,' he said.
Morgan Stanley analyst Erin Wright agrees, describing Hemsley in a research report as 'the most appropriate person to step in as CEO at this juncture in light of the recent setbacks.'
UBS analyst AJ Rice, in a report to clients, praised Hemsley as a 'steady hand to lead the company in this turbulent time.'
Hemsley will have his work cut out for him.
Beyond the reported DOJ investigation, UnitedHealth is facing intense scrutiny from multiple parts of the federal government.
In its annual report, UnitedHealth acknowledged the company 'has been involved or is currently involved in various governmental investigations, audits and reviews.'
UnitedHealth said these include 'routine, regular and special investigations, audits and reviews' by a wide range of agencies, including the DOJ, the Internal Revenue Service, the Labor Department and the Securities and Exchange Commission.
The developments have unnerved investors – especially the decision to abandon 2025 financial guidance.
Bank of America downgraded UnitedHealth from 'buy' to 'neutral' on Tuesday, warning that it could take years for the company to recover.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
U.S. Stock Futures Up on Meta, Microsoft Earnings
U.S. stock futures inched higher on Wednesday evening, buoyed by robust earnings reports from tech giants Microsoft (MSFT) and Meta Platforms (META). Futures on the Nasdaq 100 (NDX), the Dow Jones Industrial Average (DJIA), and the S&P 500 Index (SPX) were up 1.04%, 0.18%, and 0.72%, respectively, at 6:58 p.m. EDT on July 30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Microsoft and Meta, both members of the 'Magnificent Seven,' saw their shares rise 8% and 12%, respectively, in after-hours trading. MSFT surpassed revenue and earnings estimates easily and said that its annual revenue from its cloud computing service, Azure, crossed $75 billion. Similarly, Meta topped estimates and provided an optimistic third-quarter sales outlook that exceeded Street estimates. This positive after-hours session contrasted with Wednesday's regular trading session, in which the S&P 500 and the Dow Jones fell 0.12% and 0.38%, respectively. The Nasdaq Composite, however, managed a 0.15% gain. The market sentiment was influenced by the Fed Chair Jerome Powell's indications that the central bank is not yet prepared to cut interest rates. Looking ahead, investors are awaiting the June personal consumption expenditures (PCE) price index report on Thursday. Also, several companies are scheduled to report earnings tomorrow, such as Comcast (CMCSA), Apple (AAPL), Amazon (AMZN), Cigna (CI), CVS Health (CVS), AbbVie (ABBV), and Mastercard (MA).
Yahoo
2 hours ago
- Yahoo
Earnings Will Be ‘Worse Than Expected' for UnitedHealth. How Should You Play UNH Stock Here?
UnitedHealth (UNH) shares lost another 5% on July 29 after the company's management warned elevated medical costs will result in lower-than-expected earnings in 2025. The world's largest health insurer now sees its per-share earnings printing at $16 this year, well below analysts' forecast for $20.91 a share. More News from Barchart Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Here's What Happened the Last Time Novo Nordisk Stock Was This Oversold Dear Microsoft Stock Fans, Mark Your Calendars for Aug. 1 Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! UnitedHealth stock has been in a freefall since early April, and is now down more than 55% versus its year-to-date high. Medical Costs May Continue to Hurt UnitedHealth Stock UNH reassured investors that it can 'resolve issues and recapture its earnings growth potential' in its quarterly release on Tuesday, but its expectations for medical costs hardly signal improvement in the second half of 2025. According to UnitedHealth, its medical care ratio will fall between 89% and 89.5% this year, roughly the same as 89.4% recorded in the second quarter. Persistent cost pressures could restrict margin expansion in the near term and result in prolonged profitability-related challenges for the NYSE-listed firm. UNH shares are slipping today also because the insurer recently confirmed that its Medicare billing practices are under investigation by the Department of Justice (DOJ). Why UNH Shares May Still Be Worth Owning Despite the aforementioned concerns, UNH may still be worth owning as it's arguably the most important U.S. health insurer and is currently trading at a historically low multiple. According to Barchart, UnitedHealth shares are going for a price-sales (P/S) ratio of 0.64x only at the time of writing. Investors could also take heart in the fact that even in the face of major headwinds, the Minnetonka-headquartered firm reported better-than-expected revenue for its second quarter on Tuesday. Moreover, a healthy dividend yield of 3.3% makes UNH stock somewhat more attractive to own at current levels, at least for income-focused investors. Wall Street Remains Optimistic on UnitedHealth An attractive valuation is the leading reason why Wall Street firms haven't yet thrown in the towel on UnitedHealth stock. Heading into the earnings release, analysts had a consensus 'Moderate Buy' rating on UNH shares with the mean target of about $355 indicating potential upside of more than 30% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
3 hours ago
- CNN
DOJ Seeks To Unseal Epstein Grand Jury Docs - The Source with Kaitlan Collins - Podcast on CNN Podcasts
DOJ Seeks To Unseal Epstein Grand Jury Docs The Source with Kaitlan Collins 48 mins A look at what the Justice Department says is in the Jeffrey Epstein grand jury documents and statements that likely won't satisfy the MAGA base.
